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Background: Osteoporosis is a disease characterized by weak bone, affecting hun-
dreds of millions of people worldwide, predominantly postmenopausal women. The 
main clinical consequence of the disease is bone fractures and the lifetime risk of 
any fracture has been estimated at ~55% in Norwegian women. Hip and vertebral 
fractures are the two most serious fracture types, associated with substantial pain, 
disability, and even death. Even though there is consensus that patients at high risk 
of fracture should be treated, there is still a troubling treatment gap that shows few 
signs of closing. Only 6.6% of untreated patients receive treatment after their first 
fracture and there are ~225,000 untreated individuals with a bone mineral density 
indicative of osteoporosis in Sweden. An equally noteworthy aspect of undertreat-
ment is poor adherence (compliance and persistence) to treatment, i.e. how patients 
and physicians adhere to dosing instructions and treatment regimens. Many patients 
stop filling prescriptions at pharmacies prematurely (refill non-persistence) and 
this is a cause for concern with respect to effective fracture prevention. There are 
also reports that dispensings at pharmacies are too few and far between to provide 
adequate drug exposure (measured as refill compliance). Oral alendronate, a bispho-
sphonate, constitutes ~80% of all osteoporosis treatments and is generally recom-
mended for 3-5 years. Treating osteoporosis have in most industrialized countries 
been estimated to be cost-effective (compared with no treatment) but this depends 
on several factors, such as the risk of the patient population, drug costs, treatment 
effectiveness, and the treatment alternatives being compared. Treatment adherence 
is often not factored into such cost-effectiveness analyses.
Objectives: This thesis aims at addressing pharmacoepidemiologic and health 
economic aspects of poor compliance and persistence to osteoporosis treatment 
by both establishing the extent of the problem and consequences for fracture risk 
in a Swedish setting, as well as investigating how it can be incorporated into the 
health economic framework to inform reimbursement decisions and regional pri-
orities for recommended prescription standards.
The topics of health-economic value or treatment persistence are by no means 
specific to the Swedish setting. Therefore, even though the included publications 
are based on Swedish data, the background and findings are also often put in an 
international context, or entirely without reference to geography.
Methods & papers: Three of the articles used Swedish register data on pharmacy 
dispensings, diagnosis codes, and mortality. Repeat dispensings at pharmacies by 
57,000 individuals were used to estimate refill persistence and refill compliance 
as an approximation of true drug exposure. Paper I investigated the proportion of 
patients starting an osteoporosis treatment that stopped their treatment  prematurely 
at different time points, as well as the implications on the risk of fracture in groups 
stratified by refill persistence. Paper II addressed how automatic generic substitution 
(for off-patent medication) influence persistence to treatment of oral bisphospho-
nates. A natural experiment was devised for the years 2006-2009 where an off-patent 
medication was compared to an on-patent medication to isolate the effect of generic 
substitution. The effect on persistence for patients getting their first medication refill 
substituted at the pharmacy was also investigated. Paper III, amended with a new 
analysis in a larger dataset, investigated the residual effect after treatment with bis-
phosphonates on fracture risk and explored whether a healthy adherer effect (i.e. that 
patients with an inherently lower fracture risk stay longer on treatment) confounds 
the association between refill persistence and residual anti-fracture effect. Paper IV 
proposes a health economic simulation model framework for incorporating adherence 
and studying the important drivers of cost-effectiveness in this context.
Main conclusions:
• Refill persistence to typical oral osteoporosis medication estimated from 
pharmacy dispensing in Sweden is poor, with ~50% stopping treatment 
within 12 months. Prescription refill gaps among persistent patients 
appears to be a margnial problem, with 96% of patients having access to 
>80% of intended doses.
• Poor refill persistence to osteoporosis treatments is associated with an 
increased fracture risk in an exposure-dependant manner. 
• Automatic generic substitution of alendronate tablets at pharmacies was 
likely causing reduced treatment persistence to treatment during 2006-
2009. Patients who had their alendronate product substituted at the first 
prescription refill had 25% higher risk of stopping their treatment. This 
topic should be revisited in more recent data and for other therapeutic areas. 
• It is likely that treatments shorter than 6 months with oral bishposphonates 
has little effect on fracture risk.
• Oral bisphophonates taken for at least 12 months may confer a residual 
effect of 20-35% on the risk of any fracture for up to 5 years after stopping 
treatment. It is not clear if and how such a residual effect wanes with time 
after stopping treatment. The health economic implications of residual 
effect can be considerable, depending on the context.
• There is a statistically significant inverse relationship between time on 
bisphosphonate treatment and post-treatment fracture risk. This finding 
supports an assumption that the magnitude of a residual effect depends on 
the preceding time on treatment with bisphophonates in health-economic 
evaluations. 
• Incorporating treatment adherence into a health economic evaluation in 
osteoporosis can have a substantial impact, but is context specific. The 
choice of accounting for or disregarding adherence to treatment may have 
an impact on both treatment recommendations, priorities, reimbursement, 
and prices of treatments for osteoporosis.
Poor persistence to osteoporosis treatments causes increased morbidity and mor-
tality. Improving persistence to osteoporosis treatments would confer substantial 
health benefit for both patients and society. The clinical and health-economic 
consequences of persistence to osteoporosis treatments should not be disregarded 
when setting priorities and drug prices.
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1 INTRODUCTION
Osteoporosis, literally “porous bone”, is a disease characterized by weak bone. It 
is a major public health problem, affecting hundreds of millions of people world-
wide, predominantly postmenopausal women. The main clinical consequence of 
the disease is bone fractures. It has been estimated in Norwegian data that 55% of 
women and 25% of men over the age of fifty will sustain an osteoporotic fracture 
in their lifetime [1]. Approximately 70,000 fragility fractures occur every year in 
Sweden [2]. Hip and spine fractures are the two most serious fracture types, asso-
ciated with substantial pain and suffering, disability, and even death. As a result, 
osteoporosis imposes a significant burden on both the individual and society. 
During the past two decades, a range of effective medications has become avail-
able for the treatment and prevention of osteoporosis. The aim of pharmacological 
therapy is to reduce the risk of osteoporotic fractures. 
The diagnostic definitions of osteoporosis have historically been based on low 
Bone Mineral Density (BMD) and the presence of fractures, which both are risk 
factors associated with increased fracture risk. A commonly used threshold is that 
a BMD 2.5 standard deviations below that of a young healthy individual indicates 
osteoporosis and the added presence of a previous fragility fracture indicates 
established osteoporosis. There are several other known risk factors, such as age, 
sex, fall risk, use of glucocorticoids, type of previous fracture, parental fracture 
history, smoking, alcohol consumption, comorbidity, and BMI that influence risk 
assessment and treatment decisions. [3]
A majority of the most influential risk factors are associated with the individual’s 
age, which may be one of the reasons why the disease suffers from a highly prob-
lematic undertreatment. In a Swedish context, ~8.5% of untreated women and 
2.3% of untreated men are treated within a year after a fragility fracture [4], and 
about 30% of all women 70-79 years have a BMD indicating osteoporosis. ~15% 
of women 75-85 years old have been estimated to have a previously diagnosed 
hip or vertebral fracture [5].
An equally noteworthy aspect of undertreatment is poor persistence with treat-
ment. ~50% of oral treatments are discontinued within 12 months [6] even though 
treatment often is recommended for at least 3-5 years. injections or infusions with 
longer dosing intervals (annually or every 6 months) appear to be associated with 
higher levels of persistence. Generic alendronate tablets, the mainstay treatment, 
is affordable (<500 SEK/year) and cost-effective compared with no treatment, but 
its clinical utility is likely diminished by poor treatment persistence. It is therefore 
of relevance to consider how more costly treatment options with a possibly better 
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persistence profile should be regarded, not only with respect to efficacy derived 
from clinical trials, but also considering that treatments likely will be longer. 
In its 2003 report on medication adherence in general, the World Health Organization 
(WHO) quoted the statement by Haynes et al that “increasing the effectiveness of 
adherence interventions may have a far greater impact on the health of the popu-
lation than any improvement in specific medical treatments”. Poor adherence to 
medication leads to increased morbidity and death and has been reported to incur 
costs of approximately $100 billion per year in only in the United States [7].
This thesis aims at addressing pharmacoepidemiologic and health economic aspects 
of poor persistence to osteoporosis treatment by both establishing the extent of 
the problem as well as investigating how it can be incorporated into the health 
economic framework that commonly is used to inform reimbursement of new 
treatments as well as regional priorities for recommended prescription standards.
The topics of health-economic value or treatment persistence are by no means 
specific to the Swedish setting. Therefore, even though the included publications 
are based on Swedish data, the background and findings are also often put in an 




2.1.1 Brief historical outlook
In the 1830s the French pathologist Jean Georges Chretien Frederic Martin Lobstein 
noticed that some patients’ bones were riddled with larger than normal holes, and 
he coined the term osteoporosis (porous bone) to describe such deteriorated human 
bone. Somewhere around 1940 postmenopausal osteoporosis was defined in the 
US and hospitals began treating women with the condition with estrogen. In the 
1960s Herbert Fleisch discovered compounds known as bisphosphonates that 
inhibit bone resorption. However, the seriousness of the condition was not well 
recognized or acknowledged. In 1984, the National Institutes of Health publicized 
this disease, citing it as a significant threat to health and emphasizing that bone 
loss could be reduced by estrogen therapy, calcium, good nutrition and exercise. 
Such acknowledgements and inventions led to that the bisphosphonates alendronate 
and risedronate were launched as anti-osteoporosis drugs. [8]
Although the disease has been documented for many years, osteoporosis and the 
associated fractures have often been viewed as inevitable consequences of aging. 
The description of osteoporosis that is now widely accepted was formulated less 
than 20 years ago. The World Health Organization (WHO) published a report in 
1994 that provided diagnostic criteria for osteoporosis based on the measurement 
of bone mineral density (BMD) and recognized osteoporosis as an established 
and well-defined disease that affected more than 75 million people in the United 
States, Europe and Japan [9].
2.1.2 Pathophysiology
Osteoporosis is a chronic condition typically found in older adults and is caused 
by an imbalance of bone resorption in excess of bone formation. This bone remod-
eling typically increases approximately two-fold in women after menopause, and in 
the 5 to 7 years surrounding menopause, women lose approximately 12% of their 
bone mass. In this process the repairing of microdamage is slowed and calcium 
content is released from the estrogen-deprived bone into the blood stream [10].  
Osteoporosis in men is most commonly due to secondary disorders or causes, with 
use of glucocorticoids being the most common reason for secondary osteoporosis. 
Male primary Osteoporosis also exists, primarily in older men. The traditional view 
has been that testosterone is the primary sex hormone regulating bone metabo-
lism in males, but during the last two decades it has been proposed that estrogen 
deficiency in either sex is the primary precipitant of primary osteoporosis. [11]
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2.1.3 The measurements and definitions of osteoporosis
2.1.3.1 BMD
Low bone mass is an important component of the risk of fracture and the measure-
ment of bone mineral density has thus come to form the cornerstone of diagnosis, 
as well as risk fracture prediction, treatment choice and monitoring of a patient’s 
treatment [12].  
Bone mineral density (BMD) is the amount of bone mass per unit volume (volu-
metric density, g/cm3), or per unit area (areal density, g/cm2), and both can be 
measured by densitometric techniques. A large variety of techniques is available 
but the most widely used technique is dual-energy x-ray absorptiometry (DXA), 
which measures the areal density. The absorption of x-rays is sensitive to the 
calcium content of tissue, of which bone is the most important source. DXA can 
be used to assess bone mineral content of the whole skeleton as well as specific 
sites, including those most vulnerable to fracture [13]. Commonly measured sites 
are the lumbar spine, femoral neck, and total hip. 
The use of DXA is further supported by the strong association between low BMD 
and increased fracture risk. A meta-analysis by Marshall and colleagues [14] 
reported a relative risk of hip fracture of 2.6 for each standard deviation decrease 
in BMD at the femoral neck. Strong associations between BMD and risk are also 
present for many of the other skeletal sites (Table 1). It is generally the case that 
the BMD at a particular site better explains fracture risk at the same site. For 
example, a standard deviation lower BMD at the lumbar spine is associated with 
a 2.3-fold increase in the risk vertebral fractures, whereas the risk of a forearm 
fracture (distal radius) only is increased by a factor 1.7.  
Table 1. Relative risk (RR) of fracture per standard deviation (SD) in BMD (adapted 
from Marshall et al. [14])
Site of measurement Outcome fracture
Forearm Hip Spine All fractures
Distal Radius 1.7 1.8 1.7 1.4
Femoral neck 1.4 2.6 1.8 1.6
Lumbar spine 1.5 1.6 2.3 1.5
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2.1.3.2 T-score and Z-score
Per the WHO’s recommendation, the measured BMD is related to the BMD of a 
young healthy woman (25-30 years) and the T-score is calculated as the number 
of standard deviations from the reference population. For example, an individual 
with a lumbar spine (LS) BMD one standard deviation below that of healthy young 
woman will have a LS T-score of -1.0 SD. The Z-score is calculated in a similar 
fashion but where an age matched population is used for reference. Thus, if the 
example individual with a LS T-score of – 1.0 SD is 75 years old, the corresponding 
Z-score will instead be positive, because her BMD will be higher than the mean 
LS BMD among 75-year old women in the general population.     
2.1.4 Diagnosing osteoporosis
In 1994, the WHO published diagnostic criteria for osteoporosis in postmenopau-
sal women based on the T-score, intended primarily for descriptive epidemiology 
(Table 2) [9]. These criteria are still widely used, often in combination with other 
risk factors, to define diagnosis and guide treatment decisions. The term “severe 
osteoporosis” is commonly also referred to as “established osteoporosis”.
Table 2 Diagnostic thresholds based on BMD and fracture (adapted from WHO 
report [9]
Diagnosis BMD T-score (SD)
Normal ≥ -1.0
Low bone mass (osteopenia) < -1.0 but > -2.5
Osteoporosis ≤ -2.5
Severe Osteoporosis ≤ -2.5 + one or more fragility fractures
These thresholds were developed for BMD at the spine, hip and forearm. It has 
been suggested that the femoral neck should be the standard measurement site 
due to its high predictive value for hip fracture [15], whereas in Swedish clinical 
practice the lowest BMD T-score measured at the spine, total hip, or femoral neck 
is typically considered. Approximately 21% of all women 50-84 years, and around 
50% in women older than 80 years, have a T-score indicating osteoporosis if the 
refence ranges at the femoral neck is used [16] (Table 3) The commonly used ref-
erence BMD and SD are derived from the US NHANES III data [17]. There are 
local reference data available for several countries (France, Germany, UK, Sweden 
etc.) which would yield slightly different T-scores. Local differences are relatively 
small and NHANES III reference data can therefore be used for consistency [5].
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Table 3. Prevalence of osteoporosis estimated in year 2000 for Sweden , reference 





population Number (000) % of population Number (000)
50-54 2.5 7 6.3 17
55-59 3.5 7.6 9.6 21.1
60-64 5.8 11.4 14.3 30
65-69 7.4 14.2 20.2 43.7
70-74 7.8 14.6 27.9 63
75-79 10.3 13.7 37.5 68.3
80-84 16.6 14.7 47.2 67.8
50-84 6.3 83.2 21.2 310.9
2.1.5 Fracture risk assessment and the incorporation of addi-
tional risk factors
Even though the formal diagnosis of osteoporosis is based on T-score and the 
existence of prior fractures it should be noted that it is the estimated fracture risk 
that to a large extent will guide treatment decisions and disease management. A 
low BMD is associated with a relative risk of fracture of approximately 1.5-3.0 
per standard deviation but there are several other risk factors that independently 
are also associated with the risk of fracture. A patient with a relatively benign 
BMD not consistent with osteoporosis can thus still be at higher risk of fracture 
than a patient with confirmed osteoporosis. An interesting note in this context is 
that the ability of BMD to predict fracture is comparable to the use of blood pres-
sure to predict stroke, but significantly better than serum cholesterol to predict 
myocardial infarction [9]. 
Most notable of these other risk factors is age, which has a strong impact on frac-
ture risk that is independent from that of BMD and prior fracture [18].  Johnell et 
al. [19] exemplified this relationship clearly by estimating the 10-year probability 
of hip fracture at given T-score values. For example, a 50-year old woman with 
a T-score of -2.0 SD has a 10-year probability of hip fracture of 1%, whereas an 
80-year old woman with the same T-score has a probability of 10%. Even though 
two thirds of all fragility fractures occur in women, the risk at a given age and 
T-score is similar in women and men, indicating that sex should be regarded more 
as an important cause of low BMD than an independent risk factor.
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Other clinical risk factors to be considered in risk assessment are [3, 20]:
• Low body mass index
• Parental history of hip fracture
• History of fragility fracture
• Glucocorticoid treatment
• Current smoking
• Alcohol intake 3 or more units daily
• Rheumatoid arthritis
• Other secondary causes of osteoporosis
o Untreated hypogonadism in men and women, e.g. premature meno-
pause, bilateral oophorectomy or orchidectomy, anorexia nervosa, 
chemotherapy for breast cancer, hypopituitarism




o Type I diabetes
o Thyroid disorders
o Chronic obstructive pulmonary disease
o Use of proton pump inhibitors
2.1.5.1 FRAX – A tool for fracture risk assessment 
Along with age, sex, and femoral neck BMD, a number of these risk factors have 
been included in an algorithm (FRAX) estimating the 10-year probabilities of 
major osteoporotic fracture (hip, vertebral, wrist, and humerus) and hip fracture. 
The FRAX models have been developed from studying population-based cohorts 
from Europe, North America, Asia and Australia. [21, 22]
An advantage of the FRAX tool is that it combines several risk factors into one 
single metric that can be used to support treatment decisions and recommendations. 
Because the algorithms can provide fracture probabilities both with and without 
adding information about the patient’s BMD, the tool can also be used for simple 
screening in primary care, which is the setting where it may be most useful. This 
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to support the decision of whether a BMD measurement (DXA) is warranted, or 
if the patient should be treated directly, or reassured that no further action is nec-
essary. Other advantages of the algorithm include easily determined risk factors, 
global validation, application in specific regions or nations, and scores that pertain 
to both men and women. FRAX estimates the 10-year probability for men and 
women aged 40 years and older; however, it does not provide recommendations 
for how to use that information. 
Consequently, several countries have incorporated FRAX in treatment guidelines 
to provide recommendations for how the risk estimates should inform treatment 
decisions.  The Swedish guidelines have also incorporated the FRAX score, but 
still in combination with T-score and the presence of an existing fracture.
2.1.6 Defining an osteoporotic fracture
Fractures are the main clinical symptom of osteoporosis, but the definition of 
an osteoporotic fracture is not distinct. Opinions differ regarding the exclusion 
of different sites of fracture both in epidemiological studies, clinical trials, and 
health economic analyses. A common definition is to consider fractures from low 
energy trauma as being osteoporotic, or fragility fractures. “Low energy” is often 
described as being equivalent to fall from a standing height or less, or trauma that 
in a healthy individual would not give rise to fracture [23]. This implies that a 
majority of hip and forearm fractures are fragility fractures. At the age of 50 years, 
approximately 75% of people hospitalized for vertebral fractures have fractures that 
are attributable to low energy injuries, increasing to 100% by the age of 90 years 
[24]. A lack of increasing incidence with age or low BMD would indicate that a 
fracture type is unlikely to be osteoporosis related. Examples of this are fractures 
to the face, skull, fingers, hands, feet and ankles, of which many therefore often 
are disregarded in clinical trials and epidemiological studies [25].
Using appropriate definitions of fragility fractures is important to correctly estimate 
relative risks in clinical trials, avoid introducing statistical noise in the estimation 
of risk factures, characterizing the burden of disease, and estimating the health 
economic value of providing fracture preventing interventions. 
2.1.7 Health consequences of fractures
2.1.7.1 Health related quality of life (HRQOL)
Loss of HRQOL can be a result of fracture consequences in several health domains, 
such as pain with loss of physical functioning as well as social and mental con-
sequences. It is considered to be a subjective assessment of the impact of the 
fracture. HRQOL can measured both with disease specific instruments and with 
generic instruments, which are designed to be applicable across a wide range of 
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populations. Disease specific instruments in osteoporosis include Quality of Life 
Questionnaire (QUALEFFO-41), questionnaire QoL in Osteoporosis (QUALIOST), 
osteoporosis assessment questionnaire (OPAQ), osteoporosis QoL questionnaire 
(OQLQ), osteoporosis functional disability questionnaire (OFDQ), and osteopo-
rosis-targeted QoL questionnaire (OPTQoL). [26]
The advantage of disease specific instruments is that they are designed for a specific 
population and thereby can be more sensitive for detecting differences between 
groups or subtle effects of a specific condition. A disadvantage is that the results 
not easily can be compared to other populations or other diseases [26]. 
Short form 36 questionnaire (SF-36) and the Euroqol five item questionnaire (EQ-
5D) are two of the most popular generic instruments for studying quality of life 
in patients with musculoskeletal disorders. 
2.1.7.2 HRQOL estimated as quality weights and QALYs
If data describing HRQOL are captured using instruments or tariffs based in util-
ity theory, such as EQ-5D, or Health Utility Index (HUI), a quality weight can be 
derived. EQ-5D is available in versions with three (EQ-5D-3L) and five levels 
(EQ-5D-5L) of each of five dimensions of quality of life (mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression) and there is an increas-
ing number of valuation tariffs for translating the results into quality weights [27]. 
EQ-5D-3L combined with the Dolan tariff  [28] has most commonly been used 
in osteoporosis. A quality weight is based on the respondents’ choices balancing 
preferences for length of life (Time-trade-off (TTO)), or risk of death (Standard 
Gamble) on one side, and a hypothetical or experienced health state on the other 
side. For example, using TTO Dolan et al. [28] asked respondents recruited from 
the UK general population to consider hypothetical health states as defined in 
EQ-5D-3L. The respondents provided the length of time (years) in a state of full 
health that they regarded as equivalent to 10 years in each described target state. 
Negative values were estimated if a health state was deemed worse than being 
dead by the respondent. The collected responses were then analyzed in a regres-
sion model to attach quality weights that balances length of life and quality of life 
to each possible health state in EQ-5D-3L. 
Such quality weights can be used to estimate quality adjusted life-years (QALY’s), 
which often are used in cost-effectiveness analysis. A QALY is equivalent to a year 
of life at full health (weight=1.0) or several years with a reduced health, where 
the number of years depend on the quality weight of the health state of interest. 
The main advantage of the QALY is that it can be compared between groups and 
diseases, irrespective of whether mortality or reduced HRQOL is the consequence 
of the condition. 
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The quality weight multipliers during the first year after hip, clinical vertebral and 
forearm fracture relative to the pre-fracture level has been estimated at 0.70, 0.59 
and 0.96, respectively [29]. The health effects of major fractures likely extend 
beyond the first year after fracture. For example, hip [30] and vertebral [31] frac-
tures have been shown to confer long-lasting impact on HRQOL. 
2.1.7.3 Mortality
Post-fracture mortality has been reported to be higher than for non-fractured con-
trols or age and sex-matched mortality in the general population [32]. Mortality 
is generally increased for all ages and for all fractures, except for minor fractures. 
Absolute post-fracture mortality increases with age. But relative to the age and 
sex-matched general population or matched controls it decreases with increased 
age and time from the fracture. Standardized Mortality Ratios (SMRs) in women 
were reported by Bliuc et al. [32] in the range of 2.0-3.0 and 1.5-2.5 after hip 
and vertebral fractures, respectively. It is however not entirely clear how much 
of the excess mortality after a fracture that can be attributed to the fracture itself, 
rather than to comorbidity or other unobserved confounders [33, 34]. A relatively 
common assumption in health economic modeling of osteoporosis treatments is 
that 30% of the excess mortality is caused by the fracture itself [35-38] whereas 
others have computed absolute attributable mortality in different age groups [39]. 
2.1.8 Societal burden of disease
It is often reported that approximately 70,000 fragility fractures occur each year in 
Sweden [2], and this number is closer to 110,000 if a broader spectrum of fracture 
types is considered [5]. There are several studies addressing the burden of disease, 
both in terms health and costs. The most comprehensive literature-based summaries 
and models from a European perspective [5, 40] reports annual monetary costs 
in Sweden of €1.4 billion and €37 billion if the EU27 countries are considered. 
Incident fractures represented 66% of this cost, long-term fracture costs 29%, and 
pharmacological prevention 5%. About 70% of the total costs were incurred in 
individuals older than 74 years. Hip fractures were estimated to account for 54% 
of the costs, other fractures 40%, vertebral fractures 5%, and wrist fractures only 
1%. The annual number of QALYs lost ranged from about 250,000 in Germany 
to 39,000 in Sweden, with a total of 1.2 million for the EU27.  
The estimated cost of osteoporosis and fractures (€37 billion) may be compared 
to the cost of other diseases. From a European perspective annual costs have been 
estimated at €105 billion for dementia, €43.5 billion for headache, €14.6 billion for 
multiple sclerosis, and €13.9 billion for Parkinson’s disease. The cost of coronary 
heart disease and cerebrovascular disease in the European Union (25 countries) 
has been estimated at approximately €45 billion and €34 billion, respectively 
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[40]. The societal burden of disease per capita in both Sweden and Europe can be 
expected to increase over time, mainly due to demographic changes with a grow-
ing elderly population.
2.1.9 Treatments for osteoporosis
There are both pharmacological and non-pharmacological interventions for the 
treatment of osteoporosis and prevention of fractures. Nonpharmacologic inter-
ventions include calcium and vitamin D supplementation, weight-bearing exer-
cise, muscle strengthening, and fall prevention [41]. Some randomized trials have 
shown that wearing hip protectors can reduce hip fracture risk, particularly in the 
elderly living in nursing homes. A meta-analysis of well-conducted randomized 
controlled trials has, however, cast some doubt about the anti-fracture efficacy of 
this intervention [42, 43].
The major pharmacological interventions used in Sweden are the bisphospho-
nates (alendronate, risedronate, and zoledronate), denosumab, and parathyroid 
hormone. All of these are approved both for the treatment of osteoporosis and 
for preventive treatment of increased risk of fracture from use of glucocorticoids. 
Treatments should be given in combination with calcium and vitamin-D, which 
also is the standard in RCTs. The available range and relative use of treatments 
is roughly similar in Europe and the US, with alendronate weekly tablets being 
the most commonly prescribed drug. In 2018, alendronate accounted for 70-80% 
of prescribed DDDs in Sweden, followed by Denosumab (~8-10%), a 6 monthly 
subcutaneous injection, which have been increasingly used since its launch in 
2010. Zoledronate (12-month intravenous infusion) is also frequently used but 
is increasingly sold over the hospital channel, which precludes the study of its 
market shares in publicly available data. Table 4 shows the different treatments 
introduced in Europe going back to 1980.
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The effectiveness (within drug) of the available compounds varies across stud-
ies, which likely can be attributed to differences in the studied populations and 
normal statistical variation. Several meta-analyses comparing treatments to each 
other and to placebo has been published [44-47]. Results vary depending on the 
selection of RCTs for inclusion and types of meta-analytical methods used, but the 
general impression is that bisphosphonates reduce the risk of vertebral fractures 
by ~50-60 % and non-vertebral fractures by ~20-30% when compared to placebo 
+ calcium and vitamin-D. The injectable non-bisphosphonates (denosumab, teri-
paratide, Romosozumab) may be even more effective, particularly for vertebral 
fractures (RRR 70-75%), but possibly also for hip and non-vertebral fractures [48].
2.1.9.1 Generic medicines in osteoporosis
A generic drug is a medication created to be the same as an existing approved 
brand-name drug in dosage form, safety, strength, route of administration, qual-
ity, and performance characteristics. However, a generic medicine’s inactive 
ingredients, name, appearance and packaging can be different. A company can 
only develop a generic medicine for marketing once the period of exclusivity on 
the reference medicine has expired. This is usually 10 years from the date of first 
authorization [49].
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The reduction in upfront research costs and market competition brings that generic 
medicines are typically sold at substantially lower costs. Generic alternatives to 
brand alendronate (Fosamax™) entered the Swedish market in 2006. This brought 
price reductions from ~€400/year to ~€225/year in 2007 and the price of generic 
alendronate had reached ~€25/year in 2011. The period of market exclusivity for 
branded risedronate ended later but the price is currently also ~€25/year.
The Swedish system uses automatic generic substitution where the pharmacist is 
obliged to substitute the prescribed medication with the cheapest available alterna-
tive. The patient can choose to pay the difference if she wishes to instead receive 
the prescribed product. The potential downsides of generic substitution will not 
be extensively covered here but include confusion with changing product names, 
pill shape, and packaging [50], patient perceptions of inferior effectiveness [51], 
and physician skepticism [52].
2.1.10 Who should be treated according to guideline thresholds?
Who should be treated for osteoporosis is a question that is continuously revisited 
and reassessed by both the scientific community and treatment guideline groups, 
representing health authorities and osteoporosis societies. There is a robust con-
sensus that patients at high risk of fracture should be treated but the approaches 
for defining and assessing the intervention thresholds varies. Thresholds are gen-
erally based on prior fracture status, BMD T-score at the hip or spine, 10-year 
FRAX probability of hip or major osteoporotic fracture, and/or combinations of 
the individual risk factors described previously (section 2.1.5).  
The Swedish guidelines were released in 2012, with a preliminary ver-
sion in 2010. The national guidelines compile the best available evidence 
and are intended to be used in the development of regional guidelines. 
An update is currently underway, with planned release in 2020. The guide-
lines advocate treatment without information on BMD in presence of a fra-
gility fracture at the hip or vertebrae. For patients with other fracture types, a 
T score < -2.0 SD and a FRAX-probability of major fracture >15% is required. 
Patients without prior fractures should have a T-score < -2.5 SD and a FRAX-
probability >20% to be considered for treatment. 
The Swedish national guidelines can be perceived as convoluted, which possibly 
could lead to that locally developed guidelines may differ more across the coun-
try than ideal. Nevertheless, if the typical risk factors are considered it should be 
noted that approximately 460,000 individuals have been estimated to have a BMD 
femoral neck T-score <-2.5 SD [53], approximately 70,000 fragility fractures occur 
every year , and ~250,000 women and ~30,000 men have been estimated to have 
a 10-year FRAX-probability of major osteoporotic fracture >30 % [5].         
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The International Osteoporosis Foundation (IOF) has issued a general guidance 
[54] recommending that “Women aged over 65 years with a prior fragility fracture 
can be considered for treatment without the need for further assessment; BMD 
measurement may be felt more appropriate in younger postmenopausal women” 
and  also advocated treatment “at a FRAX probability equivalent to that associated 
with a prevalent fragility fracture”. The later recommendation is thus implicitly 
aligned with the traditional view of the fracture as an important risk factor that 
confers an absolute risk of fracture that increases with the patient’s age. This could 
be contrasted to the Swedish guidelines’ FRAX and T-score thresholds that are 
kept constant and separate from the patient’s age. 
It is safe to say that both international recommendations and the Swedish national 
guidelines allow treatment for a large number of individuals, but the translation 
to regional treatment recommendations, and lastly implementation into clinical 
practice, may require additional tools and reforms.  
2.1.11 Undertreatment in Sweden
Even though there is a wide range of treatments available and a robust consensus 
that patients at high risk of fracture should be treated, there is still a troubling 
treatment gap that shows few signs of closing. The most commonly cited indicator 
has been the proportion treated 6-12 months or 0-12 months after a first fragil-
ity fracture”. This indicator has not been reported since 2014 but has historically 
been estimated in the range of 12-15% during the last decade. This indicator also 
includes patients that may have been on treatment before the fracture. The guide-
lines provide a target a level of 30% for the indicator. A more recent study by 
Spångeus and colleagues [4] of only untreated patients, using otherwise largely 
similar definitions, provides a more granular picture. 6.6% of patients received 
treatment after their first fracture. There was however a clear difference between 
fracture types with estimates of 5.2% after hip fracture, 5.8% after non-hip-non-
vertebral fractures, and 21.2% after clinical vertebral fracture. The discrepancy 
between treatment after hip and vertebral fracture provides a stark contrast to 
the national guidelines, which recommends treatment, even without information 
of BMD, after both fracture types. There is also clear variability between health 
care regions in the treatment provision on the population level. Figure 1 shows 
the number of patients/1,000 inhabitants (70-79 years) that filled at least one pre-
scription for alendronate during 2019.
If a broader perspective is adopted, where penetration of osteoporosis treat-
ment is put in relationship to the population at high risk, rather than just 
post-fracture treatment, an even more disheartening picture is painted. 
Jonsson et al. [53] estimated a “treatment gap” of 59-64% in women, 
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depending on age, when the number of individuals with a BMD T-score 
<-2.5 SD was put in relation to the number of individuals filling prescriptions 
for osteoporosis medication at Swedish pharmacies. Corresponding estimates for 
men were 74-81%, indicating an even worse treatment provision in relation to the 
group level risk. In total ~225,000 untreated individuals with a BMD indicative 
of osteoporosis. The same study also assessed medication use in relation to the 
intervention threshold recommended by IOF of a FRAX probability equivalent to 
that of woman with a prior fracture and unknown BMD. Using the FRAX based 
threshold resulted in larger treatment gaps for the population 50-64 years (80% 
and 67% for women and men) and smaller treatment gaps for the population 65-79 
years (50% and 23% for women and men). The approach based on absolute FRAX 
probability does not equally favor treatment in men when compared to the analysis 
based on BMD T-score. 
Undertreatment in Sweden is considerable when adopting any of the commonly 
used definitions of high risk of fracture. However, other factors such as cost-effec-
tiveness of available treatments, unmet need, priority relative to other diseases, 
and investment needed to find the patients at high risk must also be considered 
when assessing this issue.  
Figure 1. Patients/1000 inh. (70-79 years) filling at least one prescription of alendronate 
during 2019 [55]
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2.2 Treatment compliance and persistence
Equally important to starting treatment in patients at high risk of fracture is to 
ensure that patients take the medication as prescribed and recommended. That the 
health care system and patients are failing to do so can be viewed as an additional 
component to be added to the undertreatment situation described above. 
2.2.1 Terminology
There is a wide variety of terminology for drug taking behavior in the literature. 
The term compliance is widely used, but it has been argued that the term implies 
“obedience to doctors” and that it should be termed in a way that also includes 
the active choice of the patient [56]. In line with this view, a number of alternative 
terms have been proposed: adherence, patient cooperation, therapeutic alliance, or 
concordance, referring to the agreement between patient and physician. 
In this thesis and it’s included publications terms “compliance” and “persistence” 
were used to define the following of dosing instructions and the time on treat-
ment, respectively. The term “adherence” is also often used in the literature to 
describe different permutations of compliance and persistence but is henceforth 
used as a general umbrella term for all these concepts. The prefix refill is added 
when explicitly referring to data based on prescriptions or pharmacy dispensing. 
2.2.2 Measuring adherence
The methods available for measuring medication taking behaviour can be broken 
down into direct and indirect methods of measurement. Each method has advan-
tages and disadvantages, and no method is considered the gold standard [57]. 
Examples of direct methods of measures of adherence include directly observed 
therapy, measurement of concentrations of a drug or its metabolite in blood or 
urine, and detection or measurement in blood of a biological marker added to the 
drug formulation. Indirect methods of measurement include asking the patient how 
easy it was to take the prescribed medication, performing pill counts, ascertaining 
rates of refilling prescriptions, collecting patient questionnaires, using medica-
tion event monitoring systems or asking the patient to keep a medication diary. A 
commonly used methodology is to study medication taking behavior in registers 
and claims databases where large samples based on prescriptions or pharmacy 
dispensings efficiently can be identified. Such databases are often used to produce 
two types of estimates:
1. Refill persistence, defined as the proportion of patients that at a certain 
time point still fill prescriptions without a gap in refills longer than an 
allowed period of time (e.g., 30, 60, or 90 days).
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2. Refill compliance, defined as medication possession ratio (MPR) or 
propotion of days covered (PDC). MPR is usually calculated as the 
number of days of medication available to the patient, divided by the 
number of days of observation. MPR could in theory > 100% but is often 
capped at 100%. PDC is instead defined as the proportion of the days of 
observation during which the patient has medication available, and cannot 
be estimated > 100%.
These definitions and terminology are in close agreement with those proposed by 
Cramer et al. [58] with the exception that they instead proposed that adherence 
should synonymous with compliance, whereas it in this thesis is used as a general 
term encompassing both compliance and persistence. 
2.2.3 Refill persistence
With the support of sufficient computational power and digitalized databases, 
studies of persistence and compliance to osteoporosis medication based on refill 
patterns started to appear during the first decade of the 21st century [59]. A number 
of studies using such data have been published since then, using data from dif-
ferent countries, varying methods, and definitions. The most complete and recent 
review of the literature by Karlsson et al. [60] identified 40 studies reporting the 
proportion still on treatment at 12 or 24 months after oral bisphosphonate treat-
ment start (Figure 2) . Pooled estimates were estimated at 45% and 30% after 12 
and 24 months respectively. Refill persistence was clearly higher with weekly 
dosing compared to daily but there was considerable heterogeneity in the results, 
possibly due to methodological differences between studies.
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Figure 2. Meta-analysis of 12-month refill persistence to oral bisphosphonate treatment 
(Reproduction from Karlsson et al. [60] via Open Access (http://creativecommons.org/
licenses/by-nc/4.0/)
There are also studies of persistence to denosumab (6-monthly subcutaneous 
injection) [60, 61] and zoledronate (12 monthly infusion) [62] which both have 
been reported to be associated with higher levels of refill persistence that what 
typically is seen with oral bisphosphonates.
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2.2.4 Refill compliance
Medication Possession Ratio (MPR) is another approach to describing refill behav-
ior in prescription data. MPR, expressed in percent, summarizes the number and 
length of gaps in a treatment regimen but will be highly dependent on the meth-
ods used for defining the period of observation, and whether patients are required 
to be defined as persistent during follow-up. There are several studies of refill 
compliance [63] that report MPRs of 60-70%, which however generally should 
be interpreted as a composite of refill gaps and discontinuation. MPR is largely 
similar to a measure called Proportion of Days Covered (PDC). 
2.2.5 Refill compliance and fracture risk
Studies have reported that a lower refill compliance measured as MPR is associated 
with increased fracture risk [64]. But, as stated above, most of these studies make no 
standardized distinction between refill compliance and refill persistence, meaning 
that the studied follow-up will influence the estimated level of non-adherence, and 
that it is implicitly assumed that prescription refill gaps and complete discontinu-
ation have the same impact on fracture risk. Poor refill compliance (MPR <50%) 
with bisphosphonates is associated with a clear and important increased risk of 
fractures of approximately 30–40% compared to refill compliant patients (MPR 
>80%). An MPR >80% is often used as a threshold for high adherence, where 
improved clinical outcomes can be observed. However, this threshold originates 
from a blood pressure control study and has been criticized for being arbitrary 
when extrapolated to other diseases [65].
2.2.6 Refill persistence and fracture risk
Whereas clinical trials remain the gold standard for measuring fracture reduction, 
the high internal validity required to demonstrate efficacy comes at the expense 
of external validity. The results of such trials may therefore generalize poorly 
to clinical practice, and the benefits obtained in practice might fall short of the 
anticipated benefits indicated by clinical trials. However, it is clear that also in 
randomized trials persistence with therapy declines over time [66]. Thus, any 
reduced effectiveness caused by sub-optimal adherence is to some extent already 
captured in clinical trials. 
A Dutch study using the Pharmo database [67] reported fracture risk reductions of 
12% and 46% in patients remaining adherent (MPR>80%) for 1-2 years and 3-4 
years, when compared to patients discontinuing treatment within 1 year. Lindsay 
et al. [68] reported in 2013 reductions of non-vertebral fractures of 30-45% in 
patients remaining on oral bisphosphonates for 2 years compared to those only 
filling a single prescription. 
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It has been argued that a lower fracture risk in patients remaining longer on treat-
ment partly could be due to a “healthy adherer effect” [69, 70] where patients 
who persist with therapy are generally of better health compared with patients 
who discontinue therapy early, irrespective of the reason for stopping treatment. 
2.3 Health economic evaluation and models in 
osteoporosis
2.3.1 General principles
The basic principles of health economic evaluation have been extensively described 
and discussed elsewhere [71] and is only briefly summarized here. With increasing 
health care expenditures, limited resources, and a constantly increasing availability 
of options it is important for decision makers to consider the economic impact of 
priorities. Healthcare systems are faced with a largely fixed funding envelope and 
there are limited resources available to meet all needs and demands. Therefore, 
one important objective of any healthcare system should be to maximize health 
given the limited resources. Resources should be used to ensure efficiency in the 
choices made, so that that resources are allocated in a way that implies that health is 
maximized. Economic evaluations are comparative analysis of alternative choices 
or interventions in terms of both their associated costs and consequences, irre-
spective of when in time they occur. Their purpose is to assist decisions aimed at 
improving efficiency. When two or more alternatives are compared, the alternative, 
or combination of alternatives, that confer the highest benefit should be chosen 
if the net marginal cost per unit of benefit is lower than the “willingness-to-pay” 
per additional unit of marginal benefit. 
Discounting is applied to estimate the present value of costs and health benefits 
considered in the interpretation of the analysis. This is performed to adjust for 
differences in the timing of costs and health benefits. The rationale is the “positive 
time preference,” meaning that society or an individual prefers benefits sooner 
rather than later. Costs should also be given in constant prices in a specific year, 
where price changes can be adjusted by using the consumer price index. 
The typical economic evaluation approaches in health care are:
• Cost-Minimization Analysis comparers only the cost associated with 
the evaluated alternatives. A basic assumption is that the health effects 
are presumed to be equal.
• Cost-Benefit Analysis also incorporates the health effects of the alterna-
tives but transforms the health effects to a monetary value. This generates 
a single positive or negative net present value in monetary terms of one 
21
alternative compared to another. The economic value put on health will 
thus decide the acceptable level of investment. 
• Cost-Effectiveness Analysis (CEA) estimate the incremental cost 
and effectiveness of the evaluated alternatives. An Incremental Cost-
Effectiveness Ratio (ICER) between two alternatives is then calculated. 
The effectiveness side of the ratio in a CEA can be any type of effective-
ness measure (e.g. avoided events, mmHg blood pressure, or life years). 
Cost-Utility Analysis (CUA) can be viewed as a special case of CEA 
where QALYs (see section 2.1.7.2) are used as the health outcome meas-
ure. CUA is commonly used because it allows for comparisons between 
different populations, diseases, and interventions.  
2.3.2 Evaluations of fracture prevention in osteoporosis
Cost-effectiveness evaluations of osteoporosis treatments started to emerge in the 
1980s and early 1990s but were limited by scarcity of data necessary to describe 
the natural history of the disease and the consequences of fractures [72]. The early 
models were developed in the pre-bisphosphate era and consequently evaluated 
hormone replacement therapy, also factoring in side-effects such as breast cancer, 
endometrial cancer, and endometrial hyperplasia. Since then numerous models 
have been published with ever increasing granularity of data and methods [38]. 
Besides their role in academic research they are also widely used in drug reim-
bursement decisions where a drug’s predicted health benefits and associated cost 
savings are weighed against the new intervention cost, which typically is higher 
for newer more innovative interventions. The end result, i.e. the reimbursed drug 
price will, among other things, depend on the price and effectiveness of already 
available treatment alternatives, the severity and cost of the disease, the available 
epidemiological data, the model design, the target population, and most impor-
tantly, the effectiveness and other properties of the new interventions.
Osteoporosis models are often designed as Markov Cohort Models or individual 
state transition models [71, 73]. Other model techniques, such as Decision Tree 
and Discrete Event Simulation (DES) are also available but are not described in 
detail in this thesis since they are rarely used and, in the case of DES, are sometimes 
impractical for the assessment of decision problems in both osteoporosis, as well 
as other diseases. Decision Tree models cannot easily incorporate the passing of 
time, which is a fundamental characteristic of the progression of the disease. DES 
handles a population as a discrete sequence of events in time. Each event occurs 
at a particular time-point and marks a change of state in the model. No change is 
assumed to occur between events and the simulation can “jump” to the next event 
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(DES modeling in discrete cycles is also possible). DES can allow more flexible 
and granular modeling and can be useful especially when the individual patient 
history is a key driver of future events, or if there are resource constraints [74]. 
However, DES models are less transparent, often more complex, and more chal-
lenging to validate and review [75].
In a Markov cohort model a hypothetical cohort of patients are distributed over a 
set of mutually exclusive health states and where that distribution changes over a 
pre-set number of discrete cycles, representing the passage of time. An important 
assumption of the Markov cohort model is the “no memory assumption of the 
Markovian Property”, i.e. future events only depend on the current state of the 
patient, and not on prior events. The distribution over the available health states 
is handled by transition probabilities that defines the proportion of the cohort at 
risk that should transition into a different state. 
The cohort distribution is then combined with a set of cycle and state dependent 
costs and effects. By summarising costs and effects over states and cycles, the 
average total cost and effect per patient is obtained.  
An advantage of the Markov Cohort Model is that it actually is a calculation rather 
than a simulation. This confers both the advantage of efficient testing of the model 
and instantaneous calculation of results. The major limitation is that it is inflexible 
with regards to modeling probabilities or costs that are dependent on the passing 
of time after a specific event (e.g. after a fracture) or when it is necessary to keep 
track of a patient’s history as she transitions to a different health state.
In an Individual State Transition Model, or Markov chain model, iterations of a 
hypothetical subject travel through the model one by one, instead of as a cohort. 
Each simulation will thus generate its own path through the model, generating 
distributions of outcomes, called first-order uncertainty. The approach will thus 
require enough iterations to reach stable means of the outcomes of interest (e.g. 
events, costs, and QALYs). An important feature is that the model can continuously 
store the history of each iteration, allowing future events to depend on historical 
events. For example, the occurrence of a fracture can be allowed to influence the 
probability of a future fracture in a time dependent manner. This “memory” allows 
the hypothetical patients to freely transition between health states without losing 
the information about the past. 
Alendronate, which has been the mainstay option for patients with osteoporosis, 
has generally been estimated to be cost-effective compared to no treatment [37, 
76, 77], but such results are dependent on drug costs at the time, the available 
alternatives, and the risk level of the evaluated population. Willingness-to-pay 
for health care interventions, drug costs, and fracture risk are dependent on the 
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country or even regional setting, so whether a drug should be regarded as cost-
effective becomes a local matter. Also, value-based pricing and cost-effectiveness 
are used differently by health care systems in developed countries, resulting in 
regional variance in its impact and relevance. When new treatment alternatives are 
introduced, they have typically been more costly and sometimes more effective, 
creating the need for detailed analysis of cost-effectiveness to support develop-
ment of priorities and recommendations.
2.3.3 Typical cost-effectiveness models in osteoporosis
A typical cost-effectiveness model [35, 78-80] for the evaluation of fracture pre-
venting medication in osteoporosis is designed around different fracture types or 
categories of fracture types, such as fractures to the hip, vertebrae, wrist, non-hip, 
non-hip-non-vertebrae. The types and categories used are often based on the end-
points used in the randomized clinical trials used to feed the model.  
The models typically use age dependent fracture risks for the general population 
that are modified by applying relative risks from risk factors that defines the popu-
lation of interest and risk reductions reported in clinical trials. 
The outcome of an economic evaluation in osteoporosis will depend on a range 
of data types, assumptions, and properties of the decision problem:
• Intervention and management costs of the alternatives
• Differences in fracture risk and adverse events between the compared 
alternatives
• Risk profile of the population of interest
• Health care costs and HRQOL effects of events associated with the 
evaluated alternatives. 
• Intended and actual treatment length. Many treatment regimens should last 
for 3-5 years, but this can vary for different drugs, local treatment recom-
mendations, or other factors sepcific to the evaluation being performed.
• Model properties (structure, cycle length, discounting, assumptions)
2.3.4 Residual effect after treatment in cost-effectiveness models
An important aspect of the modeling of fracture risk is what happens with it after a 
treatment is stopped, prematurely, or as intended [81]. It is unlikely that the effect 
on the bone disappears immediately when a treatment is stopped, and perhaps 
equally unlikely that it would confer fracture protection indefinitely. This period 
24
with post-treatment effect is often called “offset time” or “residual effect”. The 
residual effect has somewhat arbitrarily often been assumed to last for a number 
of years equal to length of treatment (e.g. 5+5 years) but then linearly decline 
back to the risk of an untreated patient [35, 77, 81]. This aspect may seem to be a 
minor detail but can have large implications for the estimated cost-effectiveness, 
because it confers treatment effect for no cost [81]. An analogous example is how 
progression free survival or overall survival is handled in oncology modeling, where 
assumptions regarding what happens after the time period studied in clinical trials 
can have substantial impact on the estimated health gains [82]. 
Residual effect has been studied in extensions of clinical trials where post-treatment 
protective effect on fractures has been observed for up to 30 months after PTH 
[83], and up to 15 years on BMD in small sample of women treated with HRT in 
early menopause [84]. In a small sample extension of the HORIZON trial studying 
zoledronate, a residual effect on BMD was observed when a 6 year regimen was 
compared to a 3 year regimen [85]. Increases in the risk of morphometric verte-
bral fractures have been observed after stopping treatment with both alendronate 
and zoledronate [85, 86]. Neither extension trial showed an overall reduction in 
nonvertebral fractures from continuing treatment beyond the treatment period in 
the original trials. 
In a 1-year follow-up of subjects who had completed 3 years of risedronate or 
placebo, BMD decreased in the former risedronate users but remained higher than 
in the former placebo subjects [87]. Despite the resolution of treatment effect on 
BMD, the risk of new vertebral fractures was reduced by 46% in the former rise-
dronate users compared with the former placebo subjects. 
It is not clear how large or long the residual effect on BMD and fracture risk is, if 
it applies to all fracture types, how it varies across different treatments, how long 
a treatment must be to confer a residual effect, or how and if the residual effect 
varies with the time on treatment.
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3 AIMS OF THESIS
Considerable effort and funds are committed to develop and provide pharmaceuti-
cal fracture prevention in industrialized countries, and several safe and effective 
treatments are available to prescribers and patients. However, less effort is invested 
in ensuring that medication is used to prevent as many fractures as possible. This 
thesis aims at addressing pharmacoepidemiologic and health economic aspects 
of poor refill persistence to osteoporosis treatment by both establishing the extent 
of the problem as well as investigating how it can be incorporated into the health 
economic framework that commonly is used to inform reimbursement of new 
treatments as well as regional priorities for recommended prescription standards. 
Three of the articles in this thesis are based on Swedish register data to study 
pharmacoepidemiological aspects of refill persistence to treatment and the fourth 
used a simulation model to assess the health economic implications. The specific 
objective(s) of the included articles were to:
I. Estimate refill persistence and refill compliance to treatment of primary 
osteoporosis in Sweden. A second aim was to investigate the determi-
nants of non-persistence and the association between adherence and 
fracture incidence.
II. Investigate the association between automated generic substitution and 
refill persistence with alendronate treatment of primary osteoporosis 
in Sweden.
III. Investigate the residual effect of alendronate and risedronate on fracture 
risk and assess whether a healthy adherer effect confounds the associa-
tion between refill persistence and residual anti-fracture effect.
IV. To develop a health economic model that could incorporate adherence 
and identify the important drivers of cost-effectiveness in this context.
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4 PARTICIPANTS AND METHODS
4.1 Introduction
For the three research articles addressing the pharmacoepidemiology of osteopo-
rosis included in this thesis, we used patient-level data from national registries. 
Linking of data was performed on patient level to enable analysis of outcomes 
on individual level and in relation to how and when pharmaceutical treatments 
were used. As the data sources cover essentially all patients with a fracture or 
an osteoporosis treatment in Sweden the results are representative for the whole 
population. The fourth article was based on a simulation model that synthesized 
secondary data from several other published studies. This section will summarize 
and discuss study design, data sources and other methodological aspects of the 
included articles. Papers I-III are all based on the same research dataset and will 
therefore in many cases be addressed together, whereas the modeling study will 
































































































































































































































































































































































































































































































































































































































4.2 Papers I-III 
4.2.1 Data sources
All three register studies used the national patient register and the prescribed drugs 
register. The different research datasets originate from the same data extraction, 
called the SARA (Swedish Adherence Register Analysis) study.
4.2.1.1 The National Patient Register
The National Patient Register (NPR) maintained by the National Board of Health 
and Welfare has collected data on in-patient care back to the 1960’s. Initially it 
contained information about all patients treated in psychiatric care and approxi-
mately 16 percent of patients in somatic care. The register at that time covered 6 of 
the 26 county councils in Sweden. From 1987 NPR includes all in-patient care in 
Sweden. Since 2001 the register also covers outpatient doctor visits including day 
surgery and psychiatric care from both private and public caregivers. NPR contains 
a host of variables with the most important being ICD-10 codes for diagnosis and 
procedure codes for identifying inpatient and outpatient procedures. The NPR is 
updated annually creating some delay in the possibility to study recent events.  
NPR was linked to the Swedish Prescribed Drug Register and Cause of Death 
Register when creating the SARA study extraction. The quality and accuracy of 
the national registers is high. 98.6% of all inclusions in National Patient Register, 
Prescribed Drug Register, and the Causes of Death Register are entered correctly, 
and the frequency of missing values is very low [88, 89].  
4.2.1.2 The Swedish Prescribed Drug Register
All prescriptions dispensed at Swedish outpatient pharmacies are captured in the 
Swedish Prescribed Drug Register (PDR) going back to June 2005. PDR is also 
maintained by the National Board of Health and Welfare and contains a range of 
variables. The most important variables for these studies were dispensing date, 
ATC codes, product ID, package strength, size and count, and return of medica-
tion. Being a newer register, collecting its data in a harmonized manner from the 
pharmacy IT-systems, data from PDR can be extracted with dispensing records 
close in time to the date of extraction.   
4.2.1.3 The Cause of death register
The Swedish cause of death register is a high quality virtually complete register of 
all deaths in Sweden since 1952. Although originally created for official statistics, 
it is a highly important data source for medical research since it can be linked to 
other registers. For the purposes of these studies only the date of death was used 
to be able to censor follow-up and estimate mortality.
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4.2.2 Patient selection
The PDR and NPR were linked together using the research subject’s social security 
number and pseudonymized by the National Board of Health and Welfare before 
extraction. Patients were included by either having at least one ICD-10 code in 
NPR for a fracture from 1998 and onwards (Dec 31st 2008) or by having been 
dispensed at least one osteoporosis medication in the PDR from June 2005 and 
onwards (Dec 31st 2009). Dates of death were linked to the sample (Figure 3).
Figure 3. Conceptual venn diagram of the included subjects and data sources 
The inclusion and exclusion criteria used in each study was based on the research 
questions investigated but also by considering how the patient sample could be 
defined to minimize the risk of bias:
• Paper I, which investigated refill persistence and compliance in Swedish 
osteoporosis care and its association to fracture risk, included all patients 
that were likely to have started a new treatment for osteoporosis. Patients 
with malignancies, diagnoses or treatments indicating secondary osteo-
porosis were excluded to only capture primary osteoporosis.  
• Paper II investigated refill persistence and its relation to generic substitu-
tion in patients using oral bisphosphonates and was therefore designed 
to only include such individuals. Besides excluding malignancies and 
secondary osteoporosis we also excluded patients exclusively using 
brand-name alendronate (Fosamax®) because these patients were not 
considered to be representative for the typical patient at that time. 
• In paper III we were mainly interested in the period after stopping treat-
ment and excluded therefore also patients that had not stopped their 
treatment by July 1st, 2008 to be able to require at least six months of 
follow-up for all subjects. 
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4.2.3 Study outcomes and definitions
The register-based studies, Papers I-III, focused on four types of outcomes; per-
sistence and compliance measures, generic substitution events, fractures, and 
mortality. Below are specifications and definitions of the outcomes that were used:
4.2.3.1 Persistence and compliance measures:
1. Refill persistence (Papers I-III) 
Refill persistence was operationalized as days on treatment without 
gaps longer than 8 weeks, often called “permissible gap”, or “grace 
period”. Thus, a patient was defined as non-persistent if she did not 
receive a dispensing within 8 weeks from the day that the preceding 
dispensing should have been fully consumed. If patients had accumu-
lated larger amounts of medication the definition permitted patients to 
consume their accumulated medication, as long as he/she afterwards 
filled a new prescription within the grace period.
2. Medication Possession Ratio (Paper I) 
Medication refill compliance was quantified using Medication 
Possession Ratio (MPR), defined as the number of days of medication 
available to the patient, divided by the number of days on treatment. 
For example, a patient who persisted with therapy for 365 days but only 
filled prescriptions with medication covering 325 days would have had 
an estimated MPR of (325/365) × 100≈89%. To avoid making MPR a 
composite of persistence and compliance we only estimated MPR while 
the patient was persistent. This approach is different from how it has 
been handled in many other published studies but has the advantage of 
separating two problems that may be of different magnitude, associate 
differently to outcomes, and may have different solutions.
4.2.3.2 Generic substitution events (Paper II)
The term Generic Substitution Event (GSE) was devised to describe pharmacy 
dispensings of prescriptions for the same medication to the same patient but that 
was of a different brand than the previous dispensing. 
4.2.3.3 Fractures (Papers I & III)
Fractures were identified using ICD-10 diagnosis codes. The study included the 
broad range of fracture types listed in Table 6. Only the primary diagnosis was 
used to avoid capturing historical fractures as new events. Information regarding 
the causes of the fractures (W-codes determined by the physician) that could have 
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been used to only capture low-energy trauma was available, but the coverage was 
incomplete, and all fractures were therefore included in all main analyses. It is 
not entirely clear whether the risk of cervical spine fractures and ankle fractures 
is affected by osteoporosis, but they were both included in the analyses as a con-
servative measure.
Table 6. Included fracture types
Description ICD-10 codes
Neck S12.x
Rib, Sternum, and Thoracic spine S22.x
Lumbar spine and pelvis S32.x
Shoulder and upper arm S42.x
Forearm S52.x 
Femur (including hip) S72.x
Lower leg (including ankle) S82.x
Osteoporosis with fracture M80.0, M80.2, M80.8, M80.9
4.2.4 Statistical methods and covariates
When retrospective cohorts are created from registers or other data sources it is 
often necessary to create an “index time point”. The index time point is the start 
of observation (t0) of a specific analysis and must be defined in a way so that it 
can be distinguished from other similar time points in an individual’s available 
follow-up. Examples could be the first prescription of X between dates Z and Y, or 
X days before an inpatient stay with a specific ICD-10 code. Each individual will 
have a certain amount of available follow-up that will be limited by the extracted 
time period, or lack of follow-up for other reasons that is defined by the study 
definitions. Throughout the three publications using retrospective data, analyses 
have included descriptive statistics measured at an index time point or as aver-
ages or proportions during a defined period preceding the index time point (e.g. 
2 years). The nature of the data and research question were well suited to sur-
vival analysis and hazard modeling, which was use in papers I-III. This since the 
extracted research subjects do not have a common index date (start of observation) 
because they are included retrospectively, and they also have different amounts of 
available follow-up, which necessitates right-censoring. Patients were typically 
censored at death or when reaching the date limit of the extraction, and treatment 
termination, fracture, or death was used as failure events depending on the con-
text of the analysis. Unadjusted non-parametric survival analyses were reported 
as Kaplan-Meier curves, life tables, and median time on treatment. Proportional 
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hazard models were developed for estimating adjusted hazard ratios and choice 
of distribution was made by minimizing the Akaike Information Criterion (AIC) 
and maximizing the log-likelihood. The proportional hazards assumption was 
investigated using graphical inspection and by including time dependent covari-
ates and exploring if the estimated coefficients of these regressors significantly 
varied with observation time.  
Covariates were used both to study risk factors for poor persistence but also to 
adjust for observed confounders when estimating the relationship between per-
sistence and fracture incidence. Selection of covariates (Table 7) was based on 
factors that were deemed relevant for the context rather than whether they were 
statistically significant.  
Table 7. Summary of included variables in Papers I-III





Age At index √ √ √
Sex At index √ √ √
Urban/rural region At index √ √ √
Definition from Statistics 




follow-up √ √ √
Pre-packaged medication, 





follow-up √ √ √ vs. daily regimen
Treatment type
During 
follow-up √ √ √
Low level glucocorti-
coid exposure 1 year √ √ √ Less than 2,000 mg
Gastroprotective 
treatment
1st 6m of 
OP-treatment √ √ √
PPIs, H2-antagonist, 
sucralfate, alginic acid
Prevalent fracture 5 years √ √ √
Excluding skull, fingers, 
metacarpals, face, and feet
Prevalent 
co-morbidities 5 years √ √ √








Limited by start of register 
in 2005
Calendar year at  
treatment start √
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4.2.5 Overview of study design of papers I-III
4.2.5.1 Paper I: Adherence to treatment of primary osteoporosis and its associa-
tion to fractures-the Swedish Adherence Register Analysis (SARA)
Persistence to treatment was estimated in 56,586 patients who were defined to 
have started a new treatment for primary osteoporosis based on filling prescriptions 
for osteoporosis medications. Exclusions were based on diagnoses or medication 
patterns indicative of secondary osteoporosis or malignant tumors. Treatment 
refill persistence and refill compliance were measured for up to 4 years using the 
methods described in section 4.2.3.1. Switching between the included treatments 
was allowed without being defined as non-persistent. Patient characteristics asso-
ciated with treatment discontinuation was studied using a parametric multivariate 
proportional hazards model reporting hazard ratios. The parametric models were 
specified to include age, sex, urban/rural living, weekly/daily dosing regimen, 
prevalent hospitalized fracture, individual comorbidities, pre-packaged medica-
tion (“ApoDos”), low-level exposure to glucocorticoid medication (≤ 2 g of accu-
mulated glucocorticoid medication 12 months prior to index prescription), and 
filled prescription for gastroprotective agent (proton pump inhibitor, H2-receptor 
antagonist, sucralfate, and/or alginic acid) during the first 6 months of osteoporosis 
treatment. The association between persistence and fracture at any skeletal site 
was estimated in a multiple failure model to avoid censoring patients at the time 
of first fracture and controlled for the above listed covariates. Patients were right 
censored at time of death or end of data availability.
4.2.5.2 The association between automatic generic substitution and treatment 
persistence with oral bisphosphonates
Given the marked increase in generic substitution of alendronate it was deemed 
relevant to refine the analyses in paper I by investigating if persistence patterns 
were linked to automated replacement of brand drugs with less costly generic 
alternatives. Data on product ID was used to separate otherwise identical prescrip-
tions and thereby facilitating the definition of Generic Substitution Events (GSE). 
Given that patients with long treatments statistically would experience more GSEs 
the methods were designed to avoid capturing this expected pattern:
• The proportion of dispensings constituting a GSEs and the number of 
available alendronate products during 2006 to 2009 were calculated to 
provide a backdrop for the other analyses.
• Persistence to generic alendronate was estimated for patients starting their 
treatment in 2006, 2007, 2008, or 2009. 
• A parametric multivariate proportional hazards model (Weibull) to analyse 
whether the occurrence of a GSE between the first and second prescription 
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was associated with persistence. The analysis was conducted in patients who 
had filled at least two prescriptions (i.e., being at risk of a GSE). A dummy 
variable indicating whether a patient’s first re-fill was a GSE was included 
in the model, as well as interaction terms to investigate if the patient’s age 
or sex had an impact on the association between GSEs and persistence.
• Lastly, a comparison vs. risedronate was performed. Only one risedronate 
product was available during the study period and was therefore used to 
design a natural experiment where risedronate was used as a reference 
group not at risk of GSEs.  By contrast, patients prescribed alendronate 
were at an increasing risk of experiencing a GSE between 2006 and 2009. 
Both treatments were analysed in the Weibull model described above with 
calendar year of starting treatment as dummy variables. 
4.2.5.3 Residual effect after oral bisphosphonate treatment and healthy adherer 
effects
To study the residual effect after stopping bisphosphonate treatment patients who 
had discontinued a regimen of oral bisphosphonates (OBPs) between December 
2005 and July 2008 were selected for analysis. Patients were followed from the 
time point of stopping their treatment until death or end of data availability. Patients 
were divided by time on the preceding regimen and time periods after stopping 
treatments in 12 groups, as depicted in Figure 4 below:    





0-6 months 7-12 months 12-18 monthsTime on preceding treatment
Time after stopping treatment
Figure 4. Schematic description of patient stratification in paper III
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• Fracture incidence was measured in these strata in an adjusted proportional 
hazards model, using the groups with less than one month of pre-index 
treatment as references to estimate hazard ratios.
• Time on treatment was used a continuous variable to test if it was statisti-
cally associated with post-treatment fracture incidence. 
• Patient characteristics were compared across persistence groups and 
mortality after stopping treatment was measured to assess if persistence 
was associated with the health status of the patient.  
4.2.5.4 Revisiting residual effect in paper III in a new analysis
The analysis in paper III was performed on a register extraction that covered frac-
ture diagnoses from 1998 until Dec 31st 2008 and prescription data from mid-2005 
until the end of 2009. It could be argued that this time window of linked data (~3.5 
years) was too short given the objectives and the restrictions that were put on the 
data. A new analysis with a similar design is therefore presented in this thesis, 
based on a preliminary design and thus preliminary results not yet published in a 
peer reviewed manuscript. 
The research questions that paper III only partly could address were:
• How long is the residual effect after stopping treatment with OBPs?
• Does it attenuate differently depending on the length of treatment?
• Are there other factors (unobserved confounders) that are associated with 
both treatment persistence and fracture incidence after stopping treatment?
The new analysis was performed on a larger and more recently extracted data set 
of a similar nature that covered June 2005 to December 2015 (10.5 years). Another 
difference was that the extraction included patients that either had received an 
osteoporosis medication OR had filled prescriptions for 45 Defined Daily Doses 
(DDD) of glucocorticoids (ATC H02AB). Fractures diagnosed in both the outpa-
tient and inpatient settings were included as outcomes whereas only hospitalized 
fractures were used as outcome event in research paper III. 
Similarly to the design of paper III the patients were stratified by time on treatment 
and time after stopping treatment, but longer follow-up time was now available. 
Time on treatment was divided into <1 month, 2-6 months, 7-12 months, 13-24 
months, and 25+ months, and time after stopping treatment into year 1, year 2-3, 
year 4-5, and years 6+. Beyond adjusting for patient characteristics, the analysis 
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was also contrasted to a patient sample stratified by their time on statins (ATC 
C10AA.x), instead of OBPs. Statins are cholesterol-lowering drugs and were 
chosen because:
• It is a long-term preventive treatment where treatment desicions are based 
on risk factors and refill persistence is sub-optimal (analogous to fracture 
prevention in osteoporosis).
• They are commonly used in the general population. 
• There is no reason to suspect that statins would have a protective or 
adverse effects on fracture risk. Wang et al. reported a pooled HR of 1.00 
when studying the association between statin use and fracture risk in a 
meta-analysis of 27,900 randomized participants [91].
An alternative design would have been to instead measure the risk of cardiovascular 
events in relation to refill persistence in the OBP sample. The reason for instead 
selecting a population using statins followed on fractures was that the potential 
unobserved confounding investigated should influence fracture risk, rather than 
cardiovascular outcomes.
Both cohorts were followed from stopping treatment (OBPs or statins) and frac-
ture incidence was measured in the specified time windows. When considering 
the representativeness of the statin sample it should be noted that the data material 
was drawn from patients that had filled at least one osteoporosis prescription or 
45 DDD worth of glucocorticoids. 
The rationale for performing the statin analysis was to investigate if there are 
unobserved confounders that are associated both with the exposure (pre-index 
time on treatment) and the outcome (fracture risk). Examples of such unobserved 
confounders could be propensity of falling, risk taking behavior, diet, bone min-
eral density, mobility, smoking, etc. The interpretation of an association between 
pre-index persistence to OBPs and post-index fracture risk would be strengthened 
by the absence of such an association when instead considering pre-index persis-
tence to statins. 
The two samples were run in nearly identical adjusted single failure proportional 
hazards models with interaction terms between time windows and drug exposure 
strata. Adjustment was made for age, sex, use of glucocorticoids, prior fracture, 
and Charlson Quan comorbidity index. The statin model was also adjusted for 
how patients had been included in the research data; filled prescriptions of osteo-
porosis medication or glucocorticoid medication. Results were reported as patient 
characteristics, hazard ratios and cumulative hazard functions.  
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4.2.6 Paper IV – Health economic model
Paper IV was based on the development of health economic simulation with the 
purpose of exploring how the different concepts relating to adherence could be 
included in a health economic framework and analyzing how the different aspects 
of adherence would influence the health economic assessment of an intervention 
conferring an improved adherence profile in osteoporosis. 
4.2.6.1 Model design and incorporated aspects of adherence
Health economic model analyses of pharmaceutical interventions in the osteopo-
rosis space can often be handled in a Markov cohort model framework, where a 
“memory” of past events not is necessary or can be approximated by introducing 
health states that represents the passage of time after an important event, such as 
a fracture. In a more complex context where there are several types of time points 
that contain important information, the number of states necessary in the model 
can become unpractical to handle, and other modeling techniques are therefore 
better suited. In this model design we wanted to use an individual’s time point of 
treatment discontinuation as well as the timing of different fracture events, why 
fore an individual state transition model instead was used.  
The model was designed to be able to handle and separate concepts/features that 
potentially could be of importance when incorporating medication taking behav-
ior in a health economic assessment of pharmaceuticals in fracture prevention:
• Separation of persistence (time on treatment) and compliance/adherence 
(proximity to instructions), which not necessarily would impact outcomes 
equally. The input data for these could theoretically be derived from any 
type of study and register-based refill patterns is only one method for 
linking patterns to outcomes.
o Persistence was incorporated to allow each individual model iteration 
(patient) to stop treatment in 6-month intervals. 
o Compliance was defined as a multiplicative factor (FOB=Fraction Of 
Benefit) that only should reflect sub-optimal drug-taking behaviour 
not captured by persistence. The FOB was meant as a reduction of 
the treatment effectiveness derived from a randomized trial, but the 
model did not address the likely magnitude of the FOB or how it 
should be derived.
• Possibility to allow persistence to influence the modelled residual effect 
after stopping treatment. The model could accommodate different lengths 
of a linearly declining effect. We used a base-case assumption that the time 
period with residual effect was the same as the time on treatment. I.e. a 
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patient stopping treatment after 12 months received a residual effect that 
linearly approached the effect in the comparator arm during 12 months. 
It was also possible to model fixed length that was independent from the 
time on treatment.
• A situation where the patient had been prescribed a treatment but never 
filled any prescriptions at a pharmacy was called primary non-adherence. 
Only costs for physician visits and DXA-scan was assumed. 
4.2.6.2 Model Structure, perspective, and data         
The employed model structure was largely similar to what has been used in several 
other publications evaluating interventions in osteoporosis [35, 36, 79, 92, 93]. In 
general, an individual state transition approach lends flexibility to the structure 
design where several health states and time effects can be combined, limiting 
the number of health states necessary. In this case the time-dependent post-event 
consequences after vertebral fractures and hip fractures were combined into a 
“post-fracture state” where different HRQOL-weights, mortalities, and costs was 
applied depending on a patient’s simulated fracture history. 
The analysis was done from a societal perspective, including health-care costs, 
costs of informal care, and loss of productivity. Mortality costs were not included 
in the analysis. A yearly discount rate of 3% was used for both costs and effects. 
Appropriate data on risks, effects, costs, mortality and HRQOL were collected 
from the literature. Data were taken from Swedish sources as far as possible but 
data on real world persistence to standard of care treatments were not available 
and was therefore taken from a US source [94].
4.2.6.3 Analytical scope
The model was used to compare different adherence profiles to assess the health 
economic implications of different levels of refill persistence and compliance and 
these aspects interacted with other factors such as drug prices, underlying fracture 
risk, and assumptions regarding residual effect after stopping treatment.
The base-case population was specified as a 70-year old woman without a prior 
fracture and a BMD T-score of -2.5 SD.  
Three treatment scenarios were compared to each other; “full adherence”, “partial 
adherence”, and “no treatment”: 
39
• In the full adherence scenario patients received the full treatment effect 
as estimated in randomized trials and stayed on treatment for a duration 
of 5 years. The drug cost in the full adherence arm was set at €600/year 
to emulate a newer more expensive treatment option. 
• With partial adherence patients were at risk of discontinuing treatment 
during the treatment period (based on US claims data) and only received 
80% of the treatment effect (Fraction Of Benefit) based on a theoretically 
sub-optimal refill compliance. Patients were also at risk of primary non-
adherence, where the treatment was not started at all. The drug cost in the 
partial adherence arm was set at €400/year.
• Patients receiving no treatment had the same underlying fracture risks 
but no intervention costs or treatment effects.
Model results were reported as number of fractures, costs, QALYs, Life years, 
Number Needed to Treat (NNT), and the incremental cost-effectiveness ratios 
(ICER). 
A separate measure called Variable Dependent Elasticity” (VDE) was also esti-
mated. We defined VDE as the percentage change in the ICER that occurred in 
response to a percentage change in a given variable. For example, if, in response 
to a 20% increase in the price of the high adherence drug, the ICER increased by 
30%, the VDE would be 30/20 = 0.5. i.e. a 1% increase in drug price influenced 
the ICER by +1.5%. 1,000 different model simulations were run where 10 differ-
ent model variables were allowed to freely vary ±50% in a uniform distribution. 
The 1,000 model results were then log-transformed and analysed with multivari-
ate linear regression to estimate the independent average impact of each variable 
on the ICER.   
4.3 Research ethics & funding
The studies using sensitive data have been approved by the regional ethical 
committee board at Karolinska Institutet, Stockholm (dnr 2008/1265-31/2, dnr 
2013/1543-31/4, dnr 2016/464-32). Registry based studies contain sensitive data 
on patients’ health and well-being. In these studies, only pseudo-anonymized data 
(no personal numbers) were accessible and the data were kept in a secure setting. 
Furthermore, data is only presented on aggregated level to ensure that patients are 
not identifiable in the presented results. The potential harm on patient’s lives is 
deemed to be minor whereas the increased knowledge of pharmacoepidemiologi-
cal and health economic aspects of osteoporosis may serve as a knowledgebase 
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for better and more cost-effective use of health care resources in the future which 
will benefit patients and society at large.  
Swedish research is regulated both by international conventions and international 
and national laws. The regulations aim to not damage or expose people to unneces-
sary risks when an individual’s data is used in research. For register-based research 
any caution mainly concerns the risk that information recorded and used in research 
can be wrongfully disclosed. Therefore, it is essential that the data is de-identified 
or anonymized and that there are strict rules on confidentiality and other aspects 
of personal data protection. However, it is important to note that individuals can 
also be damaged indirectly by laws and regulations that hampers research. Progress 
in terms of improved methods for patient identification, prevention and treatment 
may be delayed or hindered.
Papers I, III, and IV were executed using funds provided by Amgen inc. Amgen 
was at the time in the process of launching denosumab, which is a monoclonal 
antibody injected subcutaneously every 6 months and that has been shown to 
reduce the risk of fracture in patients with low bone mineral density. The bi-annual 
administration of denosumab confers a possibly beneficial adherence profile which 
could add health-economic value linked to avoided fractures. All sponsored manu-
scripts have been reviewed by Amgen according Amgen’s process for sponsored 
outcomes research and have been planned, executed, and interpreted with scientific 
integrity. Authorship has followed the guidelines of the International Committee 
of Medical Journal Editors (ICMJE).
This project has also been part of the Forte research programme “Increasing value 




Below is a summary of the results from each of the research papers included in 
the thesis, as well as the new analysis related to paper III.
5.1 Paper I: Persistence to osteoporosis treatments is 
poor and associated with fracture risk
We analyzed persistence to treatment with common medications indicated for 
prevention of fractures and its association to fracture incidence and patient 
characteristics.
The study describes adherence behavior of 57,000 Swedish patients. Refill per-
sistence to treatment of osteoporosis in Sweden is low and approximately 50% of 
treatment-naïve patients discontinue their treatment within 1 year from starting it. 
A total of 51%, 35%, 25%, and 14% were still on treatment (switching allowed) 
after 1, 2, 3, and 4 years, respectively. When instead adherence was measured as 
prescription refill gaps in patients still on treatment the Medication Possession 
Ratio (MPR) was estimated at 94%, indicating that persistence may be a better 
approach to characterizing the adherence challenges in the Swedish setting. When 
the sample was stratified, we could show that there were differences between differ-
ent medications and between weekly and daily dosing. The oral bisphosphonates, 
alendronate and risedronate were comparable, whilst persistence to Raloxifene (a 
Selective Estrogen Receptor Modulator) and strontium ranelate (no longer used 
in Sweden) showed higher rates of discontinuation. PTH (Parathyroid hormone) 
which is much more costly and used in more severe patients showed better persis-
tence (75% after 12 months) but with a sharp drop around 18 months, which was 
aligned with reimbursement restrictions at the time. Risk of stopping treatment 
was markedly lower (HR 0.56) for patients filling prescriptions for weekly alen-
dronate or risedronate when compared to daily dosing formulations. All results 
were generally stable when the “grace period” (or permissible gap) was varied 
between 4 and 12 weeks. 
The association between time on treatment and fracture risk is shown in Figure 5. 
Compared with <1 month of therapy, treatment for 1 month to 1 year, 1 to 2 years, 
and 2 to 3 years was associated with a lower 3-year fracture incidence (HR 0.86, 
p = 0.091; HR 0.67, p < 0.001; and HR 0.59, p < 0.001, respectively). No significant 
relationship was identified between MPR and fracture risk. 
The following patient characteristics was associated with reduced risk of stopping 
treatment; Weekly dosing regimen, undergoing a treatment switch, receiving pre-
packaged medication, female sex, and any prevalent fracture during the last 5 years.
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Living in an urban region, concomitant gastroprotective treatment, any preva-
lent comorbidity and low-level glucocorticoid exposure were all associated with 
increased risk of stopping treatment. The patient’s age did not impact the risk of 
stopping treatment.
Figure 5. Relative and absolute risk of any fracture for different levels of persistence. 
Patients with <1 month treatment as reference.  (re-use from paper II with permission 
from Springer Nature)
5.2 Paper II: Automatic generic substitution of oral bis-
phosphonates likely reduces treatment persistence
In a cohort of women and men (n=36,433) identified in the Swedish Prescribed 
Drug Register through filled prescriptions for alendronate or risedronate between 
2005 and 2009 the possible impact of automatic generic substitution was studied.
Generic alendronate appeared on the market already in 2005 but the Swedish 
Prescribed Drug Register was not available until mid-2005 which made an analy-
sis of likely treatment naïve patients before 2006 unfeasible. Between 2006 and 
2009, the number of alendronate products increased from 15 to 25, the propor-
tion of prescriptions constituting a substitution event increased from 10.8% to 
45.2%, and the proportion of patients persisting with alendronate treatment for 
12 months fell from 66.9% to 51.7%. Patients starting alendronate treatment in 
2006 had lower risk of stopping treatment compared with those starting in 2007 
(HR 1.34, 95% CI 1.29–1.39), 2008 (HR 1.49, 95% CI 1.43–1.55), and 2009 (HR 
1.50, 95% CI 1.40–1.60). 
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Irrespective of calendar year, individuals who had their alendronate product sub-
stituted at the first prescription refill had significantly higher probability of dis-
continuation (HR 1.25, 95% CI 1.20–1.30). No difference over time was observed 
in persistence with proprietary risedronate during the same period (Figure 6). The 
analysis of both patient groups was adjusted for available covariates.
Figure 6. Hazard Ratios of stopping treatment for weekly alendronate and risedronate 
between 2006 and 2009. 2006 used as reference year (*), (re-use from paper II with per-
mission from Springer Nature)
5.3 Paper III: There is likely a residual effect after treat-
ment with oral bisphosphonates, and that also is 
associated with the preceding time on treatment
Patients were followed from the time point of stopping their treatment with oral 
bisphosphonates and stratified by the preceding time on treatment.
A total of 867 hospitalized fractures were sustained during the follow-up after 
treatment discontinuation (Table 2). Hip and femur fractures were most common 
(34%), followed by forearm fractures (9%) and vertebral fractures (8%). The 
composite group “other fractures” constituted 49% of all fractures. 
Time on treatment was found to be significantly inversely associated with incidence 
of hospitalized fractures after treatment termination when adjusting for available 
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covariates, indicating that longer treatments may confer a better post-treatment 
residual effect. When the follow-up was divided into three time-windows (0-6 
months, 7-12 months, and 13-18 months) there was a marked difference in frac-
ture incidence during the first 0-6 months depending on the preceding time on 
treatment. Whether this difference persisted or attenuated over time was not pos-
sible to estimate with certainty given the limited sample and length of follow-up. 
Nonetheless, there was a trend that the effect from the preceding time on treatment 
decreased with time. 
Mortality was elevated during the first 6 months after stopping treatment in patients 
with preceding treatments longer than 12 months. The reason for this could not 
be assessed but it is possible that serious illness and deteriorating health is a more 
common reason for discontinuing longer treatments (>1 year), than is the case 
for shorter treatments. Mortality was similar across all treatment duration groups 
beyond 6 months after stopping treatment.
Patient characteristics, including prevalent fractures and co-morbidities, and post-
treatment mortality were comparable across persistence durations, and we found 
no evidence of a healthy adherer effect.  
Figure 7. Hazard Ratios of fracture after stopping treatment with alendronate or risedronate, 
stratified by preceding time on treatment and time after treatment. Preceding treatment 
<1 month used as reference in each follow-up time window. (re-use from paper III with 
permission from Springer Nature)
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5.4 Revisiting residual effect in a new analysis with new 
data
Using the methods described in section 4.2.5.4 a new analysis of residual effect 
was performed in a considerably larger dataset with longer follow-up. Results are 
preliminary and have not been published or peer reviewed elsewhere.
5.4.1 Patient characteristics
Patient characteristics were generally comparable across different levels of per-
sistence. Prior fractures were more frequent and glucocorticoid use less frequent 
in patients with treatments longer than 24 months. T-score data for the Total Hip 
and Lumbar spine were only available for a subset of patients (n = 6,190) but were 
reported as means where available. Mean and maximum follow-up was 3.4 and 
9.5 years, respectively. 
Patient characteristics for statin users (n = 132,725) are not reported here but were 
also largely comparable across different levels of persistence to statins.
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Table 8. Patient characteristics 














n 6,285 33,821 18,815 17,463 19,886 96,270
Female 85% 80% 79% 81% 86% 82%
age (mean, years) 73,0 72,0 72,7 73,0 74,9 73,0
Prior fracture (any)1 46% 48% 47% 50% 61% 51%
Prior fracture (hip)1 8,8% 9,0% 8,8% 9,2% 11,0% 9,4%
Glucocorticoid use2 35,5% 39,4% 42,7% 39,2% 26,0% 37,0%
Secondary osteoporosis 13,4% 14,1% 13,3% 11,5% 11,0% 12,8%
T-score (Total hip,  
mean SD)3 -2,04 -1,96 -1,90 -1,97 -1,98 -1,96
T-score (Lumbar spine, 
mean SD)3 -2,19 -1,94 -1,96 -2,05 -1,99 -1,99
1Going back to 2001
2Equivalent to prednisolone 5mg/day for 3 months during 12 months before index
3T-score data only available for 6,190 patients (6.4%) 
5.4.2 Cumulative incidence of any fracture
Cumulative incidence of any fracture was plotted for men and women for up to 8 
years after stopping treatment in Figure 8. The cumulative incidence during this 
period was estimated at 23% and 38% for men and women, respectively.  
Figure 8. Cumulative incidence with CI95 of any fracture after stopping treatment in women 
(female=1) and men (female=0) from the selected sample
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5.4.3 Residual effect stratified by pre-index persistence and 
follow-up time
Figure 9 shows hazard ratios of any fracture over time and stratified by preceding 
time on treatment with oral bisphosphonates. HRs are reported relative to patients 
treated for <1 month in each time period. There were little or no residual protec-
tive effect after treatments shorter than 6 months while treatments longer than 6 
months appeared to confer risk reductions in the range of 20-35% during the first 
five years after stopping treatment. Hazard ratios were not statistically different 
form the refence group beyond five years. This does not preclude that there are 
long-term protective effects beyond five years after stopping treatment, but the 
available sample did not contain enough patients with sufficiently long follow-up 




























2-6 months 7-12 months 13-24 months 25+ months
Figure 9. Adjusted HR of any fracture after stopping OBP treatment, stratified by time 
on OBPs before stopping treatment. The group with <1 month of treatment was used as 
reference in each follow-up time window.
The reference analysis (Figure 10) of the relationship between persistence to statins 
and fracture risk showed no tendency that persistence to statins was associated 





























<1 month 2-6 months 7-12 months 13-24 months 25+ months
Figure 10. Adjusted HR of any fracture after stopping statin treatment, stratified by time 
on statins before stopping treatment (n= 132,725). The group with <1 month of treatment 
was used as reference in each follow-up time window.
5.5 Paper IV: Health economic modeling indicates 
that adherence could have implications for cost-
effectiveness but that it is dependent on the analysed 
scenario, assumptions, and data.
The model was used to compare a hypothetical “fully adherent” patient group 
with a “partially adherent” group, as well as a “no treatment” option. The “partial 
adherence” alternative was designed to approximate how treatments are used in 
clinical practice, as opposed to a clinical trial setting. 
In the base-case scenario, which simulated and intended 5-year treatment, the 
partial adherence group incurred lower drug costs (-68%), higher fracture costs 
(+13%), more fractures, and fewer Life years and QALYs gained when compared 
to the “full adherence alternative”. When estimating the net differences in this 
hypothetical analysis, full adherence over 5 years costed more (+ €712), resulted 
in more Life Years and QALYs gained (+0.021/patient and +0.038/patient). The 
resulting Incremental Cost-Effectiveness Ratio (ICER) was estimated at €18,809/
QALY gained. However, the exact ICER of “full vs. partial adherence” was not 
necessarily the most relevant outcome of this article, as it mainly was used to relate 
different aspects of cost-effectiveness to each other.   
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The model was used to analyse the impact of different variables, input data, and 
assumptions. The potentially important drivers of cost-effectiveness in this context 
include (in no particular order);
• Magnitude of reduced drug effectiveness due to poor compliance
• Assumptions and data regarding offset time (residual effect after stopping 
treatment)
• The underlying fracture risk in the treated population
• The anti-fracture drug effect of the analysed interventions
• Drug prices 
• Fracture related health care costs
Other seemingly unrelated factors such as discount rates and the intended treatment 
length for a fully adherent patient also impacted results. The level of suboptimal 
treatment persistence, which is the main reason addressing this in the first place, 
was estimated to have a smaller independent impact on the model results. This 
emphasizes that all the aspects that should be taken into account when incorporat-
ing adherence into an osteoporosis model are interlinked. For example, increasing 
persistence to a very expensive but moderately effective treatment may be cost-
ineffective, depending the treatment alternative, the level of risk in the population, 
and so forth.   
Model analysis of optimal adherence was associated with fewer osteoporotic 
fractures, and the impact was more evident among those with prior fractures. The 
health benefits of adherence were often partially offset by increased intervention 
costs associated with the improved drug-taking behavior.
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6 DISCUSSION AND CONCLUSIONS
There is and has been considerable effort invested in finding and developing new 
chemical entities and formulations for the prevention of osteoporotic fractures. 
This is naturally a good thing since the patient population in question is large 
and the consequences of fractures in terms mortality, quality of life and costs are 
considerable. This effort is in many ways driven by actors on free markets whose 
intrinsic purpose is to develop new pharmaceutical products, often improving on 
what already is available, or providing treatments options for a diverse patient 
population. Nonetheless, the emergence of new treatments options may, in the case 
of osteoporosis, confer smaller potential improvements in outcomes than would 
improvements in drug delivery and case-finding. The Swedish government agen-
cies that primarily are tasked with regulating and assessing osteoporosis treatments 
in terms of effectiveness and safety (MPA1) [95], and cost-effectiveness (TLV) 
[96] focus mainly on the properties of the drug itself and less so on factors such 
as practicality of administration, convenience, or other factors that may influence 
how the drug is used. 
This thesis aimed at addressing pharmacoepidemiologic and health economic 
aspects of poor adherence to osteoporosis treatment by both establishing the extent 
of the problem as well as investigating how it can be incorporated into the health 
economic framework that commonly is used to inform reimbursement of new 
treatments as well as regional priorities for recommended prescription standards.
All three register studies (papers I-III) used the national patient register and the 
prescribed drugs register. The different research datasets originate from the same 
data extraction, called the SARA study (Swedish Adherence Register Analysis). 
Studying drug taking behaviour in register data is associated with some inherent 
limitations. For example, it is difficult to ascertain why a patient has stopped her 
treatment. It could be due to side-effects, low perceived risk due to an asympto-
matic disease, insufficient follow-up by the care giver, or a conscious decision by 
the physician to stop treatment. It is also not possible to know if a pharmacy dis-
pensing always means that the patient has consumed the medication as intended.
1  Benefits are defined on the basis of the indication sought and should generally be 
direct and concrete, such as prolonged survival, cured infection, prevented / delayed 
stroke / heart attack or reduced pain.
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6.1 Refill persistence and the relationship to fracture risk
This thesis illustrates that relative risk reduction estimated in clinical trials is too 
blunt an instrument when assessing whether a treatment is effective in a real-world 
setting. Generic alendronate has been the mainstay of pharmaceutical fracture pre-
vention in Sweden for some time and results from this thesis showed that ~50% of 
Swedish patients have stopped their treatment within 12 months after starting it. 
Treatment is generally recommended to persist for 3-5 years. The type of register 
data used here can however not address why treatment has been stopped prema-
turely. It could be due to experiencing adverse drug reactions, lack of follow-up 
and encouragement from the treating physician, or lack of motivation due to an 
asymptomatic disease in combination with concomitant medication for other condi-
tions perceived to be more important. The results from paper III studying residual 
effect suggested that treatment discontinuation may coincide with the contraction 
of conditions associated with increased mortality, which may be a justified course 
of action. Nonetheless, a study by Jonsson et al. [53] comparing osteoporosis care 
in Swedish regions showed that there were large differences across regions in the 
proportion of patients that was switched over to another option after discontinu-
ation of alendronate treatment within 12 months. Results ranged from 3-4% in 
Kronoberg and Västernorrland to 16% in Jönköping, indicating that health care 
organization and policy have substantial roles to play in improving persistence to 
osteoporosis treatment in general.
Irrespective of the underlying reasons for stopping treatment it appears to be 
associated with reduced treatment effectiveness due to insufficient drug exposure. 
Patients filling osteoporosis medication prescriptions for 2-3 years had ~40% lower 
incidence of fractures than those who had only filled prescriptions for <30 days 
of medication during the same time frame. Absolute risk reduction (ARR) was 
~5.0% over three years, meaning that one fracture could be avoided for every 20 
early dropouts that instead could be kept on treatment for 2-3 years. The analy-
ses in paper III and the new analysis contrasting the results to refill persistence 
to statins and its association to fractures did not indicate the association between 
fractures and refill persistence was confounded by a “healthy adherer effect” (i.e. 
unobserved confounding).
6.2 Refill compliance
Medication Possession Ratio (MPR) and its methodological sibling, Proportion of 
Days Covered (PDC), have been used extensively for studying adherence in retro-
spective pharmacy and prescription data [63]. The version of MPR used in paper 
I of this thesis was actually closer to the definition of PDC, given that accumula-
tion of drugs was counted for in a way that prohibited MPR from being >100%. 
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However, the main difference from other osteoporosis adherence research was that 
MPR only was measured in persistent patients, avoiding the variable to be a com-
posite of refill persistence and refill compliance. MPR in persistent patients was 
estimated at 95%, which suggests that refill persistence should be the adherence 
metric of choice in osteoporosis. This appears to be true in the Swedish context 
but studies in other health care systems are warranted. Moreover, the relationship 
to fracture risk is not necessarily the same for gaps in an ongoing treatment and 
completely stopping treatment for a longer period. 
6.3 Generic substitution
The generic substitution reform from 2005 has been estimated to have led to 
savings of approximately 8 billion Swedish kronor annually during 2007–2010. 
Such cost-savings can be an important contribution when increasing treatment 
uptake and access to new more expensive treatments that are protected by market 
exclusivity for ~10 years after their authorization. The findings in this thesis do 
however identify a possible risk related to automatic generic substitution (AGS) 
of osteoporosis at the pharmacies, namely reduced treatment persistence. If the 
estimated relative difference over time compared to proprietary risedronate are 
combined with the fracture risk results in Paper I it is plausible that AGS is the 
cause of unwanted excess risk of fractures in the osteoporotic population.
Only osteoporosis medication (oral bisphosphonates) was studied and additional 
research would be necessary to ascertain if similar patterns exist for other therapy 
areas and other types of patient populations. Neither treatment persistence studied 
in Paper I or its association to automatic generic substitution were influenced by 
age in adjusted hazard models. At least the latter finding is unexpected since cog-
nitive impairment and polypharmacy are more common among the elderly, and 
such characteristics could be suspected to interact negatively with an automatic 
replacement of the package of medicines expected by the patient. 
The study period included cohorts of patients that started their treatments in 2006-
2009, which was only 2-5 years after the reform. It cannot be excluded that some 
form of habituation has occurred since then, where patients are more accustomed 
to automatic generic substitution.  
If a negative association between AGS and persistence to preventive long-term 
treatments in general were to be established, it would highlight the need to amend 
the reform with measures to improve the situation. Possible alternatives could be 
generic prescribing, where brand names not are used in prescriber communication 
and electronic prescriptions, stricter regulations for how medicine packages should 
be labeled or shaped, or simply an evidence-based strategy for how prescribers and 
pharmacists should communicate with patients with respect to generic substitution.
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6.4 Residual effect
The unique properties of bisphosphonates (binding to bone mineral and long reten-
tion in the skeleton) provide opportunities as well as challenges for both clinicians 
[97], guidelines, and health economic evaluations. The effects on remodeling of the 
bone persist after stopping treatment, and this has led to interest in RCT extensions 
where residual effect on BMD and fractures could be studied [85-87]. However, 
RCTs typically run for 3-5 years and patients will therefore have been treated con-
siderably longer than what is the case for many patients in the real-world setting. 
The question of residual effect after osteoporosis treatments is important in dif-
ferent ways depending on the perspective adopted. One aspect is that of necessary 
length of treatment and the implications of “treatment holidays”, where a patient 
stops treatment for a longer period and then returns [98]. Reasons for considering 
such holidays are related to unnecessary costs of treatment and management and 
an increased risk of the rare but very serious atypical femur fractures after long 
exposure to bisphosphonates [99]. The FDA have suggested that a drug holiday 
may not be advisable in high-risk patients, but for patients discontinuing treat-
ment, there were no concrete recommendations on what should be done [100]. 
The results in this thesis from paper III complemented with a new preliminary 
analysis in a larger sample indicate that at least 12 months of treatment with oral 
bisphosphonates (OBPs) is necessary to achieve a residual effect post-treatment. 
However, the analysis in paper III only followed patients after stopping treatment, 
but not those staying on treatment, which precludes any conclusions regarding the 
appropriateness of treatment holidays. Conversely, the findings in paper I associ-
ating poor refill persistence to increased fracture risk indicate that remaining on 
treatment is the better option for patients at high risk of fracture.
6.4.1 The new complementary analysis of residual effect
The new analysis in this thesis was designed to fill some of the gaps left by the 
limited sample and follow-up in paper III. A refence analysis of patients with dif-
ferent levels of persistence to statins was also performed to investigate if a general 
“healthy adherer effect” could invalidate any interpretations of the relationship 
between persistence and fracture risk. An alternative design would have been to 
instead measure the risk of cardiovascular events after bisphosphonate use. The 
reason for instead selecting a statin population followed on fractures was that the 
potential unobserved confounding investigated should influence fracture risk, rather 
than cardiovascular outcomes. For example, propensity of falling or risk-taking 
behavior would not necessarily increase the risk of myocardial infarction or stroke.
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The new complementing analysis generally supported the results from paper III 
but also suggests that a residual effect of 20-35% on any fracture after OBPs may 
be maintained for up to 5 years. Whether such a long residual effect also is pre-
sent after treatment with other therapeutic options, such as denosumab, zoledronic 
acid, PTH, and the forthcoming romosozumab, is unclear but should be factored 
into the treatment choice. The reference analysis of persistence to statins showed 
no pattern that a general “adherence behavior” would be associated with lower 
fracture risk. A limitation of the new preliminary analysis is that it only was per-
formed on single failure data, meaning the patients could incur a maximum of 
one fracture during follow-up. It is possible that the estimated magnitude of the 
residual effect would increase if multiple failures were allowed, and it would also 
increase statistical power. 
The RCT extensions of patients stopping zoledronate [85] and alendronate [86] 
had limited samples but showed a statistically significant increase vs. controls in 
the risk of vertebral fractures, but not for non-vertebral fractures. These findings 
suggest that it could be appropriate to also investigate different fracture types 
separately in this larger register based sample.
6.4.2 Health economic implications of residual effect
The health economic implications of residual effect can be considerable, since it 
concerns drug effect for no additional drug cost [81]. This would be especially true 
if residual effect were shown to be different across treatments. A post-hoc analysis 
of the FREEDOM trial indicates that stopping denosumab may cause an increased 
risk of multiple vertebral fractures [101] and the effect of risedronate on Total Hip 
BMD has been reported decrease within a year from stopping risedronate [87]. 
New effective treatments may be deemed less cost-effective if there are reasons to 
believe that post-treatment fracture risk more rapidly will return to pre-treatment 
levels. Another alternative is that post-reimbursement follow-up of residual effect 
data would be required by Health Technology Assessment (HTA) bodies. 
Paper III and its complementary analysis showed that refill persistence had a clear 
impact on the post-treatment fracture risk, at least for treatments longer than 12 
months and during the first year after stopping treatment. How treatment persis-
tence interacts with residual effect over longer time is still unclear, and it was not 
specifically analyzed in the complementary analysis in this thesis. From an HTA 
perspective such a relationship could mean that persistence to treatment would 
be even more important for decisions regarding pricing and reimbursement of 
new therapies.
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6.5 Health economic modeling and adherence
Since persistence to osteoporosis treatments is sub-optimal and actual treatment 
durations for most patients are considerably shorter than what is studied in clinical 
trials it raises the question of how it should be handled in health economic evalu-
ations. When comparing a treatment to “no treatment” it is tempting to conclude 
that poor persistence will result in losing a part of the effectiveness and an equally 
large part of the intervention cost. This notion is only true if all relationships are 
proportional and independent of time, so that half of the drug exposure confers 
half the effect and that the costs, risks and consequences of disease are the same 
at the beginning and end of the evaluated time period. In the case of osteoporosis 
this is not the case. Risk of fracture increases steeply with age, and so does fracture 
related costs and mortality. Moreover, as was concluded in paper III of this thesis 
and its complementary analysis, persistence also influences the fracture risk after 
treatment. The impact of persistence can be even larger when several treatments 
with different intervention costs and effectiveness profiles are compared. 
Paper IV suggests a framework for combining the pieces of this puzzle without 
introducing double counting of costs or effects and that also is reasonably aligned 
with how data realistically can be collected. Nonetheless, incorporating adherence 
in osteoporosis models requires substantial amounts of additional data that may 
not always be available. For example, it is not possible to collect refill persistence 
data in the real-world setting for a new treatment before it enters the market.  
The modeling framework proposed in paper IV was based on a specific scenario 
that was chosen to reflect a typical osteoporosis population, but what drives cost-
effectiveness in one scenario can be of less importance in another. We therefore 
attempted to identify more universally important factors by letting model variables 
vary independently in a large number of model simulations. Results suggested 
that underlying risk of the population, residual effect, and drug costs all had con-
siderably impact on the influence of persistence for cost-effectiveness. But that 
all variables are interlinked and modulate each other’s impact is also the main 
limitation of an attempt generalize what drives the importance of persistence in 
health economic evaluation of osteoporosis treatments. 
It is advisable that those who perform or assess the incorporation of adherence in 
health economic osteoporosis models carefully consider what an assumption or 
technical solution means, not only in the direct sense, but also how it will inter-
act with other aspects of the decision problem. The choice of accounting for or 
disregarding adherence may have an impact on both treatment recommendations, 
priorities, reimbursement, and prices of treatments for osteoporosis.
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6.6 Main Conclusions
• Refill persistence to typical oral osteoporosis medication estimated from 
pharmacy dispensing in Sweden is poor, with ~50% stopping treatment 
within 12 months. Prescription refill gaps among persistent patients 
appears to be a margnial problem, with 96% of patients having access to 
>80% of intended doses.
• Poor refill persistence to osteoporosis treatments is associated with an 
increased fracture risk in an exposure-dependant manner. 
• Automatic generic substitution of alendronate tablets at pharmacies was 
likely causing reduced treatment persistence to treatment during 2006-
2009. Patients who had their alendronate product substituted at the first 
prescription refill had 25% higher risk of discontinuation their treatment. 
This topic should be revisited in more recent data and for other theraputic 
areas. 
• It is likely that treatments shorter than 6 months with oral bishposphonates 
has little effect on fracture risk.
• There is a statistically significant inverse relationship between time on 
bisphosphonate treatment and post-treatment fracture risk. This finding 
supports an assumption that the magnitude of a residual effect depends on 
the preceding time on treatment with bisphophonates in health-economic 
evaluations. 
• Oral bisphophonates taken for at least 12 months may confer a residual 
effect of 20-35% on the risk of any fracture for up to 5 years after stopping 
treatment. It is not clear if and how such a residual effect wanes with time 
after stopping treatment. The health economic implications of residual 
effect can be considerable, depending on the context.
• Incorporating treatment adherence into a health economic evaluation in 
osteoporosis can have a substantial impact, but is context specific. The 
choice of accounting for or disregarding adherence to treatment may have 
an impact on both treatment recommendations, priorities, reimbursement, 
and prices of treatments for osteoporosis.
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